|Dr. Michael T. Cullen Jr.||Co-Founder, Exec. Chairman, Pres & CEO||221.2k||N/A||1946|
|Ms. Susan Horvath||VP of Fin., CFO, Sec. & Treasurer||213k||N/A||1959|
|Dr. Thomas X. Neenan||Co-Founder & Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Tammy Groene||VP of Operations||N/A||N/A||N/A|
|Dr. Suzanne Gagnon||Chief Medical Officer & Director||N/A||N/A||1957|
Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with pancreatic cancer. The company has scientific collaborations with pancreatic disease experts Cedars Sinai Medical Center in Los Angeles, the University of Miami; the University of Florida; the Austin Health Cancer Trials Centre in Melbourne, Australia; the Ashford Cancer Centre in Adelaide, Australia; and the Blacktown Cancer and Haematology Centre in Sydney, Australia. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota.
Sun BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.